Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | PGR | P06401 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | GAPDH | P04406 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144784 | 0.84 | MAOB (0.68) | MAOBADORA3MAOACA1CA2 | |
| SCHEMBL4988885 | 0.81 | MAOB (0.55) | MAOBADORA3MAOAPGRCA1 | |
| SCHEMBL4985529 | 0.81 | MAOB (0.55) | MAOBADORA3MAOAPGRCA1 | |
| SCHEMBL15216064 | 0.79 | ALDH1A1 (0.69) | MAOBADORA3PGRGAPDHACHE | |
| SCHEMBL12611207 | 0.74 | MIF (0.62) | MAOBADORA3MAOAPGRACHE | |
| SCHEMBL4985668 | 0.72 | MAOB (0.45) | MAOBADORA3MAOAPGRCA1 | |
| SCHEMBL194955 | 0.70 | NPC1 (0.62) | MAOBPGRACHEKDM4EKMT2A | |
| SCHEMBL13870285 | 0.69 | MAOB (0.57) | MAOBADORA3MAOAPGRGAPDH | |
| SCHEMBL14506707 | 0.68 | MAOB (0.84) | MAOBADORA3MAOA | |
| SCHEMBL20593839 | 0.67 | NPC1 (0.49) | MAOBADORA3MAOAPGRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8192717-B2 | Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening | NAGASAKI UNIVERSITY (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | Mori, Hiroshi (JP) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131367-A1 | Composition For Diagnosing Amyloid-Related Diseases | APP, APBA1, FABP7 | MAOB 2191/4885ADORA3 3221/4885MAOA 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.